Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
History of migraine for longer than 6 months.
Free from migraine 24 hours before each dosing.
Judged to be in good health.
Nonsmoker
You may not be if
Under age of legal consent.
Legally or mentally incapacitated or has significant emotional problems.
Taking any medications from about 2 weeks before the first dose of study medication.
Has had surgery or donated blood or participated in another investigation study within 4 weeks prior to screening
Currently a regular user of any illicit drugs or has a history of drug/alcohol abuse within about 2 years
Consumes more than 6 caffeinated beverages per day
Clareo Health | Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)
